Qube Research & Technologies LTD Trevi Therapeutics, Inc. Transaction History
Qube Research & Technologies LTD
- $82.3 Billion
- Q1 2025
A detailed history of Qube Research & Technologies LTD transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 126,229 shares of TRVI stock, worth $782,619. This represents 0.0% of its overall portfolio holdings.
Number of Shares
126,229Holding current value
$782,619% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding TRVI
# of Institutions
142Shares Held
85.3MCall Options Held
1.5MPut Options Held
304K-
Nea Management Company, LLC Timonium, MD11.4MShares$70.5 Million6.78% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.3MShares$63.6 Million4.06% of portfolio
-
Rubric Capital Management LP New York, NY4.54MShares$28.1 Million0.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.84MShares$23.8 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.49MShares$21.6 Million5.95% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $362M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...